Bridging Therapy With CAR T-Cell Therapy in LBCL

News
Video

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.

Recent Videos
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Related Content
Around the Helix: Cell and Gene Therapy Company Updates – June 18, 2025

Around the Helix: Cell and Gene Therapy Company Updates – June 18, 2025

Noah Stansfield
June 18th 2025
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman
May 29th 2025
Podcast

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

John Evans, MBA, CEO of Beam Therapeutics

Beam’s Base-Editing HSC Therapy BEAM-101 Raises HbF Levels in Patients With Sickle Cell Disease

Noah Stansfield
June 16th 2025
Article

Beam Therapeutics’ team provided insight on data the company presented at EHA's 2025 Congress.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman
April 8th 2025
Podcast

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

Omotayo Fasan, MRCP, DTM&H, MBBS, the head of the clinical development program at Galapagos

Omotayo Fasan, MRCP, DTM&H, MBBS, on Evaluating CAR-T GLPG5101 in R/R NHL

Omotayo Fasan, MRCP, DTM&H, MBBS;Noah Stansfield
June 15th 2025
Article

The head of the clinical development program at Galapagos discussed the company's data presented at EHA's 2025 Congress.

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine and the clinical director of cancer cell therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine

CAR-T KITE-363's Safety Profile in R/R B-Cell Lymphoma

Saurabh Dahiya, MD, FACP;Noah Stansfield;Ashling Wahner;Caroline Seymour
June 14th 2025
Article

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine, discussed safety and efficacy data from a phase 1 trial for Kite's CD19/CD20-directed CAR-T.

© 2025 MJH Life Sciences

All rights reserved.